drugset

drugset / Trial / NCT05847920

Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

NCT05847920 ↗

Phase 2 Terminated 53 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR - 2010 injection in patients with primary IgA nephropathy.

Timeline

Start: 2023-06-04
Primary completion: 2025-01-20
Completion: 2025-01-20

Outcome

Outcome not reported

Stopped (Business): “Based on the adjustment of the R \& D strategy, the sponsor decides to terminate the research.”

Publications

Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-2010	Unknown	—	—

Indications